As per Global Insight services’ assessment, about 70+ prominent pharma and biotech giants are working on 70+ drugs in the Crohn’s Disease – pipeline landscape globally. Crohn’s Disease Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies : https://www.globalinsightservices.com/request-sample/GIS31220
Crohn’s disease is a type of inflammatory bowel disease and is a chronic disease that causes inflammation, swelling and irritation in digestive tract. Crohn’s disease most commonly occurs in the small intestine and the colon. It can affect any part of your gastrointestinal (GI) tract, from the mouth to the anus.
The exact cause of Crohn’s disease is unknown. Risk factors of developing the condition, including autoimmune disease, genetic causes, and smoking.
Report Highlights
Global Insight Service’s, Crohn’s Disease – Drug Pipeline Landscape, 2023 report provides an overview of the Crohn’s disease pipeline drugs. This report covers detailed insights on Crohn’s Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Crohn’s Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Key Players
- 4D Pharma Plc
- AbbVie
- Abivax SA
- Aclaris Therapeutics Inc
- AgomAb Therapeutics NV
- AIBIOS Co Ltd
- Alpha Cancer Technologies Inc
- Amytrx Therapeutics Inc
- Anterogen Co., Ltd.
- Artizan Biosciences Inc
- AstraZeneca
- Atlantic Healthcare Plc
- Avalo Therapeutics Inc
- Avexegen Therapeutics Inc
- Avobis Bio, LLC
- Boehringer Ingelheim
- Bristol-Myers Squibb
Buy Now : https://www.globalinsightservices.com/checkout/single_user/GIS31220
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/